8:01 AM ET
8-K
Clinical Trial Data
Vaxcyte Clinical Trial Data
Vaxcyte announced positive topline results from its OPUS-1 pivotal Phase 3 trial of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate for adults. The trial met all prespecified primary immunogenicity and safety endpoints, demonstrating noninferiority to Prevnar 20 and Capvaxive. These results will support a planned Biologics License Application (BLA) submission to the FDA in the first half of 2028.
- Earnings call
- Oct 5, 2026, 8:00 AM ET